BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20309686)

  • 21. Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.
    Kuo WH; Wu YC; Wu CY; Ho KC; Chiu PH; Wang CW; Chang CJ; Yu CT; Yen TC; Lin C
    Acad Radiol; 2012 Jun; 19(6):685-92. PubMed ID: 22459646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.
    Yang W; Fu Z; Yu J; Yuan S; Zhang B; Li D; Xing L; Zhao D; Mu D; Sun X; Fang Y; Huang Y; Li W
    Lung Cancer; 2008 Jul; 61(1):35-43. PubMed ID: 18177978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
    Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
    Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
    Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
    Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
    Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
    J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
    Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
    Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
    Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
    Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
    Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings.
    Konishi J; Yamazaki K; Tsukamoto E; Tamaki N; Onodera Y; Otake T; Morikawa T; Kinoshita I; Dosaka-Akita H; Nishimura M
    Respiration; 2003; 70(5):500-6. PubMed ID: 14665776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
    Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
    Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.